An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 2 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by Beijing Tiantan Hospital · Observational
The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. However, the long-term outcomes of MMD with conservative management remain unknown. Also, some first-degree relatives who are carriers of genetic variants occasionally manifest with intracranial arterial stenosis. Therefore, it is significant to detect the long-term outcomes of conservative treatment in MMD patients and their first-degree relatives, and thus provide potential pathogenesis of MMD.
60 studies on the registry are indexed under Moyamoya Disease; 25 are open to participants now.
This study's planned enrollment of 400 is above the median of 120 across 29 observational studies indexed under Moyamoya Disease.
Browse Moyamoya Disease studies →Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria. Relatives will be recruited from the first-degree relatives of patients with MMD.
Exclusion Criteria:
Other: Conservative management
Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Cerebrovascular events
Time frame: 6 months
Cerebrovascular events
Time frame: 1 year
Cerebrovascular events
Time frame: 2 years
Cerebrovascular events
Time frame: 5 years
Identification of RNF213 variants
Time frame: Baseline
Unfavorable neurological outcome (mRS>2)
Time frame: 6 months, 1 year, 2 years, and 5 years during follow-up
Change in cerebral perfusion status as assessed by CTP
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in immunological, inflammatory, angiogenesis biomarkers of peripheral blood
Serum, plasma, RNA, immune cells and cytokines
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in angiographic features as assessed by CTA
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in angiographic characteristics as assessed by MRA
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in radiological characteristics as assessed by HR-MRI
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tiantan Hospital